EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ACAD: Acadia Pharmaceutica

03 Sep 2025
LAST:

25.72

CHANGE:
 0.03		OPEN:
25.89		HIGH:
26.09		ASK:
35.44		VOLUME:
1.36M
CHG(%):
0.12		PREV:
25.69		LOW:
25.36		BID:
34.15		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Sep 2525.8926.0925.3625.721.36M
02 Sep 2525.9926.5025.6725.692.28M
29 Aug 2526.1926.3025.8225.991.32M
28 Aug 2526.4326.6526.1126.232.21M
27 Aug 2525.8226.6225.7826.572.53M
26 Aug 2525.3425.7525.1425.722.27M
25 Aug 2525.6625.9525.2625.322.05M
22 Aug 2524.9725.8124.9025.743.42M
21 Aug 2524.7625.0724.6324.79999K
20 Aug 2524.8125.0824.4724.94933.8K

COMPANY PROFILE

Name:Acadia Pharmaceutica
About:ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:12830 El Camino Real, San Diego, CA, United States, 92130
Website:https://www.acadia.com
CUSIP:004225108
CIK:0001070494
ISIN:US0042251084
FIGI:BBG000BHG9K0
LEI:529900O3044NO0PEA039

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:18.77
Price to Book:5.14
Price to Sales:4.13
EBITDA:103.97M
Shares:168.71M
Market Cap:4.339B

TECHNICAL INDICATORS

MA5:26.04
MA10:25.67
MA20:25.24
MA50:23.51
MA100:21.25
MA200:19.39
STO9:50.14
STO14:56.13
RSI14:55.38
WPR14:-41.67
MTM14:1.19
ROC14:0.05
ATR:0.68
Week High:26.65
Week Low:25.36
Month High:26.65
Month Low:23.28
Year High:26.65
Year Low:13.40
Volatility:15.70